Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
448 participants
INTERVENTIONAL
2005-09-30
2007-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
NCT00500331
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
NCT00495469
Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone
NCT00402909
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
NCT06579105
A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus
NCT02851849
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pioglitazone
GW677954
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* To be eligible for Randomization into the trial, a subject must satisfy all of the following glycemic criteria:
* HbA1c level via central laboratory at the pre-screening visit
* If HbA1c ≥ 8.0% but ≤ 10.0%: subject may proceed to Randomization;
* If HbA1c ≥ 7.8% but \< 8.0%, subject not eligible to proceed, but may be retested once to establish eligibility (or lack thereof). If HbA1c level ≥ 8.0% upon retest, subject is eligible to proceed; otherwise they should be withdrawn.
* If HbA1c \< 7.8%, subject not eligible to proceed (no retest allowed).
* FPG level via central laboratory at the pre-screening visit must be \< 270 mg/dL (15.0 mmol/L). FPG may be retested within a week to confirm eligibility (or lack thereof).
* Concurrent T2DM therapy:
* Diet and/or exercise treated: Must not have taken antidiabetic medication for at least 2 months prior to the pre-screening visit, OR
* Metformin monotherapy: Subjects entering the study on metformin must be on the same dose, formulation and regimen of metformin for at least 2 months prior to the pre-screening visit, AND
* TZDs and insulin are excluded in the 3 months prior to the Screening visit for all subjects.
* Males and females who are 18 to 70 years of age inclusive at the time of Screening.
* If female, eligible to enter and participate in this study:
* If of non-childbearing potential (i.e., physiologically incapable of becoming pregnant (tubal ligation), including any female who is post-menopausal \[\>1 year without menstrual period\]); or,
* If of child-bearing potential, has a negative pregnancy test at Screening (serum), at Randomization (urine) and:
* Has a male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject, or
* Uses double-barrier methods of contraception; condoms with the use of caps (with spermicide) and IUDs are acceptable, or
* Uses hormonal contraceptives (oral, depots, patches etc) with double- barrier methods of contraception as outlined above, or
* Abstains from sexual intercourse, or
* Is with a same sex partner and does not participate in bisexual activities where there is any risk of pregnancy.
* Body Mass Index (BMI): ≥25 and ≤40 kg/m² and weigh at least 50 kg at Screening.
* If subject is a smoker, must be able to abstain while in clinic at each visit.
* Subject has given full written informed consent prior to any study related procedures are performed.
Exclusion Criteria
* Diagnosis of Type 1 diabetes mellitus
* Uncorrected thyroid dysfunction. (NOTE: subjects with hypothyroidism on a stable dose of thyroid replacement therapy for at least 1 month prior to Screening, and who have a screening thyroid stimulating hormone (TSH) within the upper limit of normal may participate).
* Significant weight gain or loss (defined as \> 5% of total body weight) within the 3 months prior to Screening.
* Previous use of insulin for treatment of hyperglycemia within 3 months of Screening.
* History of recent clinically significant cardiovascular disease including:
* History or ECG evidence of prior myocardial infarction within 6 months prior to Screening.
* Current unstable angina or history of unstable angina in past 6 months.
* Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery that is either planned or occurred in the 6 months prior to Screening.
* Clinically significant arrhythmia or valvular heart disease.
* Congestive heart failure (CHF) with New York Heart Association (NYHA) Class II-IV symptoms (see Section 15.4, Appendix 4).
* Blood pressure \> 160/100 mmHg or resting heart rate \> 100 bpm. Note: subjects using antihypertensives \[e.g., beta blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II antagonists, calcium channel blockers and diuretics\] must be on stable doses during the 30 days prior to Screening and during the trial.
* Has a QTc interval (Bazett's) \> 440 msec in males and \> 450 msec in females at Screening.
* Clinically significant ECG abnormalities which, in the opinion of the Investigator, may affect the interpretation of safety data, or which otherwise, contraindicates participation in a clinical trial with a new chemical entity.
* History of chronic pancreatitis.
* Familial hypercholesterolemia.
* TGs ≥800 mg/dL (8.96 mmol/L) at Screening.
* Serum creatinine at screening \> 1.4 mg/dL (124 µmol/L) for women, or \> 1.5 mg/dL (133 µmol/L) for men.
* Clinically significant anemia defined by hemoglobin concentrations \<12.0 g/dL or \< 120.0 g/L for males and \< 11.0 g/dL or \< 110.0 g/L for females.
* History of significant co-morbid diseases (e.g., cholelithiasis, gastrointestinal disease, etc.) that would preclude participation in the study.
* Documented history of hepato-biliary disease including a history of, or positive laboratory results for hepatitis (hepatitis B surface antigen and/or hepatitis C antibody) at Screening, and/or clinically significant hepatic enzyme elevation including:
•Any one of the following enzymes greater than 2.5 times the upper limit of normal (ULN) value at Screening:
* Alanine aminotransferase (ALT)
* Aspartate aminotransferase (AST)
* Alkaline phosphatase (ALP)
* Total or direct bilirubin \> 1.5 times the ULN at Screening, unless consistent with presumed or diagnosed Gilbert's disease.
* History of metabolic acidosis, rhabdomyolysis, myalgia, myositis or myopathy after taking statins or fibrates.
* Any subject who has withdrawn therapy due to AEs after taking a PPARγ or a PPARα/γ dual agonist, either marketed (e.g., troglitazone, rosiglitazone or pioglitazone) or under current or previous clinical investigation.
* Signs or symptoms of myositis at Screening (or upon 1 repeat test), and/or creatinine phosphokinase (CPK)≥3.0 times ULN
* Is currently taking or has taken any of the following medications in the 3 months prior to the pre-screening visit:
* Anti-obesity agents (including fat absorption blocking agents)
* St. John's Wort
* Warfarin and other oral anticoagulants (excluding aspirin and non-steroidal anti-inflammatory drugs)
* Digoxin
* Oral or injectable corticosteroids (inhaled and intranasal steroids are acceptable)
* Use of antidiabetic agents (other than metformin) in the 2 months prior to the pre-screening visit.
* Use of TZDs in the 3 months prior to the pre-screening visit.
* Methotrexate, cyclosporine or monoclonal antibodies (e.g., alemtuzumab, gemtuzumab ozogamicin, rituximab, trastuzumab, ibritumomab, tiuxetan) for rheumatoid arthritis or psoriasis.
* Atypical antipsychotic medications \[e.g., aripiprazole (Abilify), risperidone (Risperdal), clozapine (Clozaril), olanzapine (Zyprexa), quetiapine (Seroquel), and ziprasidone (Geodon)\].
* Antiretroviral drugs
* Use of lipid lowering agents within 3 months prior to the pre-screening visit. This includes statins, fibrates, ezetimibe (Zetia), niacin and bile acid sequestrants.
* Monoamine oxidase inhibitors
* History of cancer except for the following:
* Basal cell carcinoma or superficial squamous cell carcinoma treated by local excision.
* Cervical cancer in situ treated definitively more than 6 months prior to screening.
* Women who are lactating, pregnant, or planning to become pregnant.
* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to any drug chemically related to the study drug.
* Known allergy to any of the capsule excipients, or history of drug or other allergy, which, in the opinion of the responsible study physician, contradicts participation. Hypersensitivity to metformin or any of its components (for subjects entering on metformin).
* Has a history of substance and/or alcohol abuse within the past year as determined by the Investigator at screening or during treatment:
* Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.
* History of alcohol abuse defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a half-pint of beer or 1 measure of spirits or 1 glass of wine.
* Received treatment with a new molecular entity (investigational drug) during the previous 4 months or participated in any other trial during the previous 3 months, or has participated in a previous study with GW677954. A new molecular entity is defined as any compound not in Phase 3. (The washout is from last dose of investigational product in the previous study until the first dose of investigational product.)
* Likely to be non-compliant, in the investigator's opinion, with respect to the protocol and related scheduled visits.
* Subject has any concomitant medical condition which in the opinion of the investigator makes them unsuitable to participate in the study.
* Subject is either an immediate family member of a participating investigator, study coordinator, employee of an investigator; or is a member of the staff conducting the study.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Northport, Alabama, United States
GSK Investigational Site
Chandler, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Alhambra, California, United States
GSK Investigational Site
Artesia, California, United States
GSK Investigational Site
Huntington Beach, California, United States
GSK Investigational Site
Inglewood, California, United States
GSK Investigational Site
Irvine, California, United States
GSK Investigational Site
La Jolla, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Northridge, California, United States
GSK Investigational Site
Norwalk, California, United States
GSK Investigational Site
Pasadena, California, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Santa Monica, California, United States
GSK Investigational Site
Tustin, California, United States
GSK Investigational Site
Vista, California, United States
GSK Investigational Site
West Hills, California, United States
GSK Investigational Site
Denver, Colorado, United States
GSK Investigational Site
Norwich, Connecticut, United States
GSK Investigational Site
Hollywood, Florida, United States
GSK Investigational Site
Hollywood, Florida, United States
GSK Investigational Site
Largo, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Saint Cloud, Florida, United States
GSK Investigational Site
Sarasota, Florida, United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Duluth, Georgia, United States
GSK Investigational Site
Honolulu, Hawaii, United States
GSK Investigational Site
Springfield, Illinois, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
West Yarmouth, Massachusetts, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Henderson, Nevada, United States
GSK Investigational Site
Henderson, Nevada, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Pahrump, Nevada, United States
GSK Investigational Site
Albuquerque, New Mexico, United States
GSK Investigational Site
Santa Fe, New Mexico, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Greensboro, North Carolina, United States
GSK Investigational Site
Cleveland, Ohio, United States
GSK Investigational Site
Franklin, Ohio, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
East Providence, Rhode Island, United States
GSK Investigational Site
Greer, South Carolina, United States
GSK Investigational Site
Simpsonville, South Carolina, United States
GSK Investigational Site
Cite, Tennessee, United States
GSK Investigational Site
Kingsport, Tennessee, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Tyler, Texas, United States
GSK Investigational Site
Salt Lake City, Utah, United States
GSK Investigational Site
West Jordan, Utah, United States
GSK Investigational Site
Virginia Beach, Virginia, United States
GSK Investigational Site
Edmonds, Washington, United States
GSK Investigational Site
Everett, Washington, United States
GSK Investigational Site
Monroe, Washington, United States
GSK Investigational Site
Wauwatosa, Wisconsin, United States
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina
GSK Investigational Site
Córdoba, Córdoba Province, Argentina
GSK Investigational Site
San Juan, , Argentina
GSK Investigational Site
Miranda, New South Wales, Australia
GSK Investigational Site
Carina Heights, Queensland, Australia
GSK Investigational Site
Spring Hill, Queensland, Australia
GSK Investigational Site
Adelaide, South Australia, Australia
GSK Investigational Site
Keswick, South Australia, Australia
GSK Investigational Site
Port Lincoln, South Australia, Australia
GSK Investigational Site
Box Hill, Victoria, Australia
GSK Investigational Site
Ringwood East, Victoria, Australia
GSK Investigational Site
Langley, British Columbia, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Greater Sudbury, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Mississauga, Ontario, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Smiths Falls, Ontario, Canada
GSK Investigational Site
Thornhill, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Waterloo, Ontario, Canada
GSK Investigational Site
Bonaventure, Quebec, Canada
GSK Investigational Site
Granby, Quebec, Canada
GSK Investigational Site
Laval, Quebec, Canada
GSK Investigational Site
Longueuil, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Saint-Marc-des-Carrieres, Quebec, Canada
GSK Investigational Site
Sainte-Foy, Quebec, Canada
GSK Investigational Site
Sainte-Foy, Quebec, Canada
GSK Investigational Site
Sainte-Foy, Quebec, Canada
GSK Investigational Site
Sherbrooke, Quebec, Canada
GSK Investigational Site
Bogotá, , Colombia
GSK Investigational Site
San José, Provincia de San José, Costa Rica
GSK Investigational Site
Cheb, , Czechia
GSK Investigational Site
České Budějovice, , Czechia
GSK Investigational Site
Olomouc, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Quito, , Ecuador
GSK Investigational Site
Cēsis, , Latvia
GSK Investigational Site
Daugavpils, , Latvia
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Riga, , Latvia
GSK Investigational Site
Tukums, , Latvia
GSK Investigational Site
Tijuana, Baja California Norte, Mexico
GSK Investigational Site
Durango, Durango, Mexico
GSK Investigational Site
Pachuca, Hidalgo, Mexico
GSK Investigational Site
Cuernavaca, Morelos, Mexico
GSK Investigational Site
Monterrey, Nuevo León, Mexico
GSK Investigational Site
Mexico City, , Mexico
GSK Investigational Site
Auckland, , New Zealand
GSK Investigational Site
Auckland, , New Zealand
GSK Investigational Site
Christchurch, , New Zealand
GSK Investigational Site
Rotorua, , New Zealand
GSK Investigational Site
Tauranga, , New Zealand
GSK Investigational Site
Lima, Lima Province, Peru
GSK Investigational Site
Lima, Lima Province, Peru
GSK Investigational Site
San Isidro, Lima region, Peru
GSK Investigational Site
Lima, , Peru
GSK Investigational Site
Moscow, , Russia
GSK Investigational Site
Perm, , Russia
GSK Investigational Site
Samara, , Russia
GSK Investigational Site
Tyumen, , Russia
GSK Investigational Site
Ufa, , Russia
GSK Investigational Site
Yaroslavl, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Statistical Analysis Plan
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Annotated Case Report Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADG20001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.